GSK says EMA validates cancer drug submission
GSK
1,353.50p
16:40 14/11/24
-0.62%
-8.50p
GSK said the European Medicines Agency had validated the its submission for a potential new indication of its treatment for a type of gynaecological cancer known as mismatch repair deficient primary advanced or recurrent endometrial cancer.
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
The move comes after the first part of a phase 3 trial of its Jemperli (dostarlimab) treatment in combination with chemotherapy for adult patients.
As a result, the EMA's Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission regarding marketing authorisation for the potential new indication.
Reporting by Frank Prenesti for Sharecast.com